TITLE 16 OCCUPATIONAL AND PROFESSIONAL
LICENSING
CHAPTER 2 ACUPUNCTURE
AND ORIENTAL MEDICINE PRACTITIONERS
PART 19 EXPANDED
PRACTICE CERTIFICATIONS
16.2.19.1 ISSUING AGENCY: New
Mexico Board of Acupuncture and Oriental Medicine.
[16.2.19.1 NMAC - Rp, 16.2.19.1
NMAC, 6/16/2015]
16.2.19.2 SCOPE: All doctors
of oriental medicine who are certified for expanded practice or who are applicants
for certification for expanded practice, as well as all educational programs
and students enrolled in an educational program.
[16.2.19.2 NMAC - Rp,
16.2.19.2 NMAC, 6/16/2015]
16.2.19.3 STATUTORY AUTHORITY: This
part is promulgated pursuant to the Acupuncture and Oriental Medicine Practice
Act, Section 61-14A-8.1.
[16.2.19.3 NMAC - Rp,
16.2.19.3 NMAC, 6/16/2015]
16.2.19.4 DURATION: Permanent.
[16.2.19.4 NMAC - Rp,
16.2.19.4 NMAC, 6/16/2015]
16.2.19.5 EFFECTIVE DATE: June 16, 2015, unless a later date is cited at the end of a section.
[16.2.19.5 NMAC - Rp,
16.2.19.5 NMAC, 6/16/2015]
16.2.19.6 OBJECTIVE: This
part lists the certification requirements for each of the following expanded
practice categories: basic injection therapy, injection therapy, intravenous
therapy and bioidentical hormone therapy.
[16.2.19.6 NMAC - Rp,
16.2.19.6 NMAC, 6/16/2015]
16.2.19.7 DEFINITIONS:
A. The
definitions in this section are in addition to those in the act and Section 7
of 16.2.1 NMAC.
B. The following
definition applies to the rules and the act: “educational course” is a comprehensive foundation of studies, approved by the
board leading to demonstration of entry level competence in the specified
knowledge and skills required for the four respective certifications in
expanded practice; an educational course is not an educational program as this
term is used in the act and the rules and as defined in 16.2.1 NMAC.
C. The following
definitions are from 16.19.36 NMAC for clarification of regulations for doctors
of oriental medicine, certified in expanded practice;
(1) “Air changes per hour” (ACPH) means the
number of times a volume of air equivalent to the room passes through the room
each hour.
(2) “Ante-area” means an ISO
Class 8 or better area where personnel hand hygiene and garbing procedures,
staging of components, order entry, CSP labeling, and other high-particulate
generating activities are performed. It
is also a transition area that:
(a) provides assurance that pressure
relationships are constantly maintained so that air flows from clean to dirty
areas; and
(b) reduces the
need for the heating, ventilating, and air-conditioning (HVAC) control system
to respond to large disturbances.
(3) “Aseptic Technique” means proper
manipulation of preparations to maintain sterility
(4) “ASHP” American Society of Health-Systems
Pharmacists.
(5) “Beyond-use
date” (BUD) means the date, or as appropriate, date and time, after which a
compounded preparation is not to be used and is determined from the date and
time the preparation is compounded.
(6) “Biological safety cabinet” (BSC) means
a ventilated cabinet that provides ISO Class 5 environment for CSP’s, provides
personnel, preparation, and environmental protection having an open front with
inward airflow for personnel protection, downward high-efficiency particulate
air (HEPA)-filtered laminar airflow for preparation protection, and
HEPA-filtered exhausted air for environmental protection.
(7) “Buffer
area” means an area where the primary engineering control (PEC) is
physically located. Activities that
occur in this area include the staging of components and supplies used when
compounding CSP’s.
(8) “Certification”
means
independent third party documentation declaring that the specific requirements have been met.
(9) “Cleanroom” means a room in which the concentration of airborne particles is
controlled to meet a specified airborne particulate cleanliness class.
Microorganisms in the environment are monitored so that a microbial level for
air, surface, and personnel gear are not exceeded for a specified cleanliness
class.
(10) “Closed system vial-transfer device” means a vial-transfer system that allows no
venting or exposure of substances to the environment.
(11) “Compounded
sterile preparations” (CSP’s) include, but are not limited, to the following dosage forms
which must be sterile when administered to patients:
(a) parenteral
preparations;
(b) aqueous
bronchial and nasal inhalations;
(c) injections
(e.g. colloidal dispersions, emulsions, solutions, suspensions);
(d) irrigations
for wounds and body cavities;
(e) ophthalmic
drops and ointments; and
(12) “Compounding aseptic isolator”
(CAI) means an enclosed ISO Class 5 environments for
compounding pharmaceutical ingredients or preparations. It is designed to
maintain an aseptic compounding environment within the isolator throughout the
compounding and material transfer processes. Air exchange into the
isolator from the surrounding environment should not occur unless the air has
first passed through a microbial retentive filter (HEPA minimum).
(13) “Critical
area” means an ISO
Class 5 environment.
(14) “Critical site” means a location
that includes any component or fluid pathway surfaces (e.g., vial septa,
injection ports, beakers) or openings (e.g., opened ampules, needle hubs)
exposed and at risk of direct contact with air (e.g., ambient room or HEPA
filtered), moisture (e.g., oral and mucosal secretions), or touch
contamination. Risk of
microbial particulate contamination of the critical site increases with the size
of the openings and exposure time.
(15) “Direct compounding area” (DCA) means
a critical area within the ISO Class 5 primary engineering control (PEC) where
critical sites are exposed to unidirectional HEPA-filtered air, also known as
first air.
(16) “Disinfectant”
means an agent
that frees from infection and destroys disease-causing pathogens or other
harmful microorganisms, but may not kill bacterial and fungal spores. It refers to substances applied to inanimate
agents, usually a chemical agent, but sometimes a physical one.
(17) “Home care” means health care provided in the patient’s
home (not a hospital or skilled nursing facility) by either licensed health
professionals or trained caregivers. May include hospice care.
(18) “Immediate use” means
administration begins not later than one hour following the start of the
compounding procedure. Use of Immediate
use products is reserved to those events in which delay in preparation would
subject the patient to additional risk due to delay in therapy and meeting
USP/NF 797 (Immediate-Use CSP Provision) criteria.
(19) “ISO 5” means air containing no
more than 100 particles per cubic foot of air of a size at least 0.5 micron or
larger in diameter (3520 particles per cubic meter).
(20) “ISO 7” means air containing no
more than 10,000 particles per cubic foot of air of a size at least 0.5 micron
or larger in diameter (352,000 particles per cubic meter).
(21) “ISO 8” means air containing no more than 100,000
particles per cubic foot of air of a size at least 0.5 micron or larger in
diameter (3,520,000 particles per cubic meter).
(22) “Laminar airflow” means a
non-turbulent, non-mixing streamline flow of air in parallel layers.
(23) “Laminar airflow workbench” (LAFW)
means a ventilated cabinet for compounding of sterile preparations. Provides preparation protection with
high-efficiency particulate air (HEPA) filtered laminar airflow, ISO Class 5. Airflow may be horizontal (back to front) or
vertical (top to bottom) in direction.
(24) “Media-fill test” means a test
used to qualify aseptic technique of compounding personnel or processes and to
ensure that the processes used are able to produce sterile preparation without
microbial contamination. During this test, a microbiological growth medium such
as soybean-casein digest medium is substituted for the actual drug product to
simulate admixture compounding. The issues to consider in the development
of a media-fill test are media-fill procedures, media selection, fill volume,
incubation, time, and temperature, inspection of filled units, documentation,
interpretation of results, and possible corrective actions required.
(25) “Multiple-dose container” means
a multiple-unit container for articles or preparations intended for parenteral
administration only and usually containing antimicrobial preservatives. Once opened or entered, a multiple dose
container with antimicrobial preservative has a BUD of 28 days unless otherwise
specified by the manufacturer.
(26) “Negative pressure
room” means a room that
is at a lower pressure than the adjacent spaces and therefore, the net flow of
air is into the room.
(27) “Parenteral product” means any
preparation administered by injection through one or more layers of skin tissue.
(28) “Personal
protective equipment” (PPE) means items such as gloves, gowns, respirators, goggles, face shields,
and others that protect individual workers from hazardous physical or chemical
exposures.
(29) “Plan of care” means an individualized care plan for each
patient receiving parenteral products in a home setting to include the
following:
(a) description of actual or potential drug therapy problems and
their proposed solutions;
(b) a description of desired outcomes of drug therapy provided;
(c) a proposal
for patient education and counseling; and
(d) a plan specifying proactive objective
and subjective monitoring (e.g. vital signs, laboratory test, physical
findings, patient response, toxicity, adverse reactions, and noncompliance) and
the frequency with which monitoring is to occur.
(30) “Positive pressure room” means a
room that is at a higher pressure than the adjacent spaces and, therefore, the
net airflow is out of the room.
(31) “Preparation” means a CSP that
is a sterile drug or nutrient compounded in a licensed pharmacy or other
healthcare-related facility pursuant to the order of a licensed prescriber; the
article may or may not contain sterile products.
(32) “Product” means a commercially
manufactured drug or nutrient that has been evaluated for safety and efficacy
by the FDA. Products are accompanied by full prescribing information, which is
commonly known as the FDA-approved manufacturer’s labeling or product package
insert.
(33) “Quality assurance” means a
program for the systematic monitoring and evaluation of the various aspects of
a service or facility to ensure that standards of quality are being met.
(34) “Quality control” means a system
for verifying and maintaining a desired level of quality in a preparations or
process, as by planning, continued inspection, and corrective action as
required.
(35) “Single-dose container” means a
single-dose, or a single-unit, container for articles or preparations intended
for parenteral administration only. It is intended for a single use. Examples of single-dose containers include
prefilled syringes, cartridges, fusion-sealed containers, and closure-sealed
containers when so labeled.
(36) “Secondary
engineering control” means the ante area and buffer area or cleanroom in which primary
engineering controls are placed.
(37) “Segregated
compounding area” means a designated space, either a demarcated area or room, that is
restricted to preparing low-risk level CSP’s with 12-hour or less BUD. Such
area shall contain a device that provides unidirectional airflow of ISO Class 5
air quality for preparation of CSP’s and shall be void of activities and
materials that are extraneous to sterile compounding.
(38) “Standard
operating procedure” (SOP) means a written protocol detailing the required standards for
performance of tasks and operations within a facility.
(39) “Sterile” means free from bacteria or other living
microorganisms.
(40) “Sterilization by
filtration” means passage of a fluid or solution through a sterilizing grade
membrane to produce a sterile effluent.
(41) “Sterilizing
grade membranes” means membranes that are documented to retain 100 percent
of a culture of 107 microorganisms of a strain of Brevundimonas (Pseudomonas) diminuta per square centimeter of membrane surface under a pressure of not less
than 30 psi. Such filter membranes are nominally at 0.22 mm or 0.2 mm porosity,
depending on the manufacturer’s practice.
(42) “Unidirectional
flow” means airflow
moving in a single direction in a robust and uniform manner and at sufficient
speed to reproducibly sweep particles away from the critical processing or
testing area.
(43) “USP 797” United States Pharmacopeia Chapter 797
Pharmaceutical Compounding.
(44) “Sterile
Preparations” - This general Chapter provides procedures and requirements for
compounding sterile preparations. General
Chapter 797 describes conditions and practices to prevent harm to patients that
could result from microbial contamination, excessive bacterial endotoxins, variability in intended strength, unintended chemical and
physical contaminants, and ingredients of inappropriate quality in compounded
sterile preparations.
(45) “USP/NF standards” means United
States pharmacopeia/national formulary.
[16.2.19.7 NMAC - Rp,
16.2.19.7 NMAC, 6/16/2015]
16.2.19.8 EXPANDED PRACTICE CERTIFICATION
GENERAL PROVISIONS: The four categories of expanded practice
certification authorized by 61-14A-8.1, NMSA 1978 and defined in 16.2.19 NMAC
that include, basic injection therapy, injection therapy, intravenous therapy
and bioidentical hormone therapy shall all include the following provisions:
A. a doctor of
oriental medicine or enrolled in an educational course shall be authorized to
perform the techniques and shall have the prescriptive authority, for the
duration of the course, to administer and compound the substances that are
authorized in the expanded practice formulary for which he is studying under
the supervision of the board approved teacher for that educational course;
under other circumstances the student shall not be authorized to obtain,
prescribe or dispense such substances;
B. upon receipt of
a current copy of CPR/BLS card the board shall annually renew the expanded
practice certifications of a doctor of oriental medicine in good standing if
the licensee has completed all continuing education required by 16.2.9 NMAC;
C. all expanded
practice and prescriptive authority certifications shall automatically
terminate when licensure as a doctor of oriental medicine:
(1) is placed on inactive status as specified in 16.2.15 NMAC;
(2) expires as specified in 16.2.8 NMAC; or
(3) is suspended, revoked or terminated for any reason as
defined in 16.2.12 NMAC;
D. Proof of completion of an ASHP course relative to USP 797
is required for the first time renewal of basic injection therapy.
E. an expanded practice certification that is revoked or
terminated shall not be reinstated; the doctor of oriental medicine must
reapply for expanded practice certification as a new applicant;
F. all expanded practice certifications that were
automatically terminated due to inactive status, expiration or suspension as
specified in Subsection E of 16.2.19.8 NMAC, shall be automatically reinstated
when licensure as a doctor of oriental medicine is reinstated, provided that:
(1) all fees required by 16.2.10 NMAC have been paid;
(2) all continuing education requirements specified in 16.2.9
NMAC have been completed; and
(3) all other relevant, reinstatement provisions, required by
board rule, have been completed;
G. each year the board may review the expanded practice
formularies for necessary amendments; when new substances are added to a
formulary, appropriate education in the use of the new substances shall be
approved and required by the board and the board of pharmacy for doctors of
oriental medicine applying for new certification or as continuing education for
renewal of the applicable expanded practice certification or certifications;
H. a doctor of
oriental medicine certified for a category of expanded practice under 16.2.19
NMAC that authorizes the use of testosterone, a controlled substance, and any
other drug that is classified as a controlled substance, shall register with
the federal DEA (drug enforcement agency) prior to obtaining, prescribing,
administering, compounding or dispensing the controlled substance;
I. a doctor of
oriental medicine certified for expanded practice, when prescribing, shall use
prescription pads printed with his or her name, address, telephone number,
license number and his or her specific expanded practice certifications; if a
doctor of oriental medicine is using a prescription pad printed with the names
of more than one doctor of oriental medicine, the above information for each
doctor of oriental medicine shall be on the pad and the pad shall have a
separate signature line for each doctor of oriental medicine; each specific
prescription shall indicate the name of the doctor of oriental medicine for
that prescription and shall be signed by the prescribing doctor of oriental
medicine;
J. a doctor of
oriental medicine certified for expanded practice shall always, when diagnosing
and treating a patient, use the skill and care ordinarily used by reasonably
well-qualified doctors of oriental medicine similarly certified and practicing
under similar circumstances, giving due consideration to the locality involved;
failure to comply with this fundamental requirement may result in denial,
suspension or revocation of licensure or certification, or other disciplinary
measures, pursuant to the provisions of the act, Section 61-14A-17, NMSA 1978, and
the Uniform Licensing Act, Section 61-1-1, et seq., NMSA 1978;
K. when a doctor of
oriental medicine is certified for injection therapy, this certification
automatically supersedes his certification for basic injection therapy; and
L. the provisions for certification transition from extended prescriptive authority (Rx1) and expanded prescriptive authority (Rx2) to the expanded practice categories specified in 16.2.19 NMAC.
[16.2.19.8 NMAC - Rp,
16.2.19.8 NMAC, 6/16/2015]
16.2.19.9 EXPANDED PRACTICE CERTIFICATION
BOARD REQUIREMENTS:
A. The board shall
have final authority for certification of all applicants.
B. The board shall
notify the applicant in writing by mail postmarked no more than 30 days after
the receipt of the initial application as to whether the application is
complete or incomplete and missing specified application documentation.
C. The board shall
notify the applicant in writing by mail postmarked no more than 30 days after
the notice of receipt of the complete application sent out by the board,
whether the application is approved or denied.
D. If the
application is denied, the notice of denial shall state the reason the
application was denied.
E. In the interim
between regular board meetings the board’s chairman or an authorized designee
of the board shall approve an expanded practice certification to a qualified
applicant who has filed, with the board, a complete application and complied
with all requirements for expanded practice certification. The temporary expanded practice certification
will be ratified by the board on the date of the next regular board meeting. Final expanded practice certification shall
only be granted by the board.
F. the board shall
maintain a list of each doctor of oriental medicine who is certified for each
expanded practice category and shall notify the New Mexico board of pharmacy of
all such certified licensees;
G. The board shall
have the authority to deny, suspend, revoke or otherwise discipline an expanded
practice certification, in accordance with the Uniform Licensing Act, 61-1-1 to
61-1-31, NMSA 1978, for reasons authorized in the act and clarified in 16.2.12
NMAC.
[16.2.19.9 NMAC - Rp,
16.2.19.9 NMAC, 6/16/2015]
16.2.19.10 EXPANDED
PRACTICE SCOPE OF PRACTICE: (from 16.2.2.10 NMAC):
A. In addition to the scope of practice outlined in section 16.2.2 NMAC for a doctor of oriental medicine in New Mexico, the scope of practice for those certified in expanded practice shall include certification in any or all of the following modules: (61-14A-8.1B, NMSA 1978) basic injection therapy, injection therapy, intravenous therapy and bio-identical hormone therapy as specified in 16.2.19 NMAC.
B. The scope of practice for those doctors of oriental medicine certified in expanded practice shall also include the expanded practice and prescriptive authority defined in 61-14A-8.1C, NMSA 1978.
[16.2.19.10 NMAC - Rp,
16.2.19.10 NMAC, 6/16/2015]
16.2.19.11 BASIC INJECTION THERAPY CERTIFICATION: The
board shall issue, to a doctor of oriental medicine, certification for basic
injection therapy upon completion of the course prerequisites including 30
hours of Pharmacology as specified in Section 9 of 16.2.18 NMAC and the
following requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form
provided by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the basic injection therapy educational course specified in
16.2.18 NMAC.
[16.2.19.11 NMAC - Rp,
16.2.19.11 NMAC, 6/16/2015]
16.2.19.12 INJECTION
THERAPY CERTIFICATION: The board shall issue to a doctor of oriental
medicine, certification for injection therapy, upon completion of the following
requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form
provided by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of:
(1) current certification by the board for basic injection
therapy; or
(2) any course combining basic injection therapy and injection
therapy, as they are specified in the board’s rules, or otherwise in accordance
with law, must be completed within two years of the start of the course.
E. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the injection therapy educational course approved by the board.
[16.2.19.12 NMAC - Rp,
16.2.19.12 NMAC, 6/16/2015]
16.2.19.13 INTRAVENOUS THERAPY CERTIFICATION:
The board shall issue
to a doctor of oriental medicine, certification for intravenous therapy, upon
completion of the course prerequisites including board certification in basic
injection therapy, and three hours of college level biochemistry, and the following
requirements.
A. The doctor of
oriental medicine shall be a doctor of oriental medicine in good standing.
B. The doctor of
oriental medicine shall submit to the board the completed application form
provided by the board.
C. The doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC.
D. The doctor of
oriental medicine shall submit, with the application, proof of successful
completion of an intravenous therapy educational course approved by the board.
[16.2.19.13 NMAC - Rp,
16.2.19.13 NMAC, 6/16/2015]
16.2.19.14 INTRAVENOUS THERAPY EXPANDED
PRACTICE CERTIFICATION: The
board shall only issue
certification to applicants after successful completion of the Intravenous
Therapy Expanded Practice Course, and
successful completion and documentation of a practicum to include 300 hours
under the supervision of a board approved physician and 150 individual patients
to be completed within two years of completion of the coursework.
[16.2.19.14 NMAC - N, 6/16/2015]
16.2.19.15 BIOIDENTICAL HORMONE THERAPY
CERTIFICATION: The board shall issue to a doctor of oriental
medicine, certification for bioidentical hormone therapy, upon completion of
the following requirements:
A. the doctor of
oriental medicine shall be a doctor of oriental medicine in good standing;
B. the doctor of
oriental medicine shall submit to the board the completed application form
provided by the board;
C. the doctor of
oriental medicine shall pay the application fee for expanded practice
certification specified in 16.2.10 NMAC; and
D. the doctor of
oriental medicine shall submit, with the application, proof of successful
completion of the bioidentical hormone therapy educational course approved by
the board.
[16.2.19.15 NMAC - Rp,
16.2.19.14 NMAC, 6/16/2015]
16.2.19.16 EXPANDED PRACTICE CERTIFICATION RENEWAL: If a doctor of oriental medicine certified for expanded prescriptive
authority does not complete all expanded prescriptive authority continuing
education requirements specified in Section 9 of 16.2.9 NMAC before the end of
the 60-day grace period, the expanded prescriptive authority certification is
expired and that licensee shall not be certified for expanded prescriptive
authority until the continuing education is completed. Provided that all other renewal requirements
have been received by the board, such a licensee shall continue to be licensed
as a doctor of oriental medicine and is authorized for that scope of practice
but shall not be authorized for the relevant expanded prescriptive authority
scope of practice. For an expired
expanded prescriptive authority certification, if a properly completed
application for certification renewal, including proof of completion of the
required expanded prescriptive authority continuing education, is received at the
board office within one year of the last regular renewal date, the expanded
prescriptive authority certification shall be renewed if all the requirements
of late certification renewal during the 60-day grace period provided by
61-14A-15, NMSA 1978 are completed, in addition to the requirements of Section
11 of 16.2.8 NMAC, and the licensee also pays the fee for expired certification
renewal specified in 16.2.10 NMAC. The
licensee must notify the board of the correct current mailing address and of
any address changes within ten days of the change. A doctor of oriental medicine who fails to
renew an expired license by the next July 31 annual license renewal date or who
fails to complete any required continuing education specific to his
prescriptive authority certification shall be required to reapply as a new
applicant for expanded practice, certification the expired license number of
any doctor of oriental medicine certified in expanded practice who fails to
renew in a timely manner in accordance with board rules. The Board will promptly report to the board of
Pharmacy when the expired license is renewed or reinstated.
[16.2.19.16 NMAC - Rp,
16.2.19.15 NMAC, 6/16/2015]
16.2.19.17 TRANSITION PROVISIONS:
A. A doctor of
oriental medicine, previously certified for extended prescriptive authority
including prolotherapy, (Rx1) as of the effective
date of this section, shall be automatically certified for basic injection
therapy and prolotherapy using previously taught and
appropriate injection routes and only substances listed in Paragraph (1) of
Subsection F of 16.2.20.8 NMAC under the provisions of Section of 16.2.19.11
NMAC.
B. A doctor of
oriental medicine, previously certified for the expanded prescriptive authority
(Rx2) as of the effective date of this section, shall be automatically
certified for:
(1) injection therapy under the provisions of Section 16.2.19.12
NMAC basic injection therapy certification is automatically superseded
by injection therapy certification;
(2) intravenous therapy under the provisions of Section of 16.2.19.13
NMAC; and
(3) bioidentical hormone therapy under the provisions of Section
of 16.2.19.15 NMAC.
[16.2.19.17 NMAC - Rp,
16.2.19.16 NMAC, 6/16/2015; A, 1/4/2020]
16.2.19.18 LICENSE DESIGNATION: The
designation for expanded practice shall follow the license number on the
license and shall reflect the respective modules of certification: Rx basic
injection, Rx injection, Rx intravenous, Rx hormones.
[16.2.19.18 NMAC - Rp,
16.2.19.17 NMAC, 6/16/2015]
16.2.19.19 ULTRASOUND CREDENTIALING: A licensed doctor of oriental medicine may
utilize musculoskeletal diagnostic ultrasound and ultrasound guidance of
procedures with the RMSK credential from the Alliance for Physician Certification
& Advancement or APCA, or the Registered Musculoskeletal Sonographer
credential from ARDMS, the American Registry of Diagnostic Sonography. A
licensed doctor of oriental medicine (DOM) who wishes to practice diagnostic
musculoskeletal ultrasound and ultrasound guidance of procedures shall register
with the board of acupuncture and oriental medicine (BAOM) to be provisionally
credentialed to practice diagnostic musculoskeletal ultrasound and ultrasound
guided procedures upon completion of a minimum of 30 hours in BAOM approved
courses. Within 36 months of provisional credentialing, the doctor of oriental
medicine shall submit to the BAOM proof of scheduling for RMSK testing with APCA
or Registered Musculoskeletal Sonographer testing with ARDMS. If the provisional credentialing period is
continued to 36 months without ARDMS RMSK or APCA RMSK credentialing, the provisionally
credentialed DOM shall submit proof of 30 hours of continuing education in
courses approved by the BAOM. Provisional credentialing shall lapse
within 48 months of initial provisional credentialing. Ultrasound credentialing
does not require certification in expanded practice.
[16.2.19.19 NMAC - Rp,
16.2.19.18 NMAC, 6/16/2015; A, 1/4/2020]
History
of repealed material.
16.2.19 NMAC, Expanded Practice Certifications, filed 10/29/2009, repealed 6/16/2015.